GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Net Debt Paydown Yield %

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Net Debt Paydown Yield % : -0.11% (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Longboard Pharmaceuticals's Net Debt Paydown Yield % was -0.11%.


Longboard Pharmaceuticals Net Debt Paydown Yield % Historical Data

The historical data trend for Longboard Pharmaceuticals's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Net Debt Paydown Yield % Chart

Longboard Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
- - -0.05 0.02

Longboard Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.13 -0.07 0.02 -0.09

Competitive Comparison of Longboard Pharmaceuticals's Net Debt Paydown Yield %

For the Biotechnology subindustry, Longboard Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longboard Pharmaceuticals's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Longboard Pharmaceuticals's Net Debt Paydown Yield % falls into.



Longboard Pharmaceuticals Net Debt Paydown Yield % Calculation

Longboard Pharmaceuticals's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 0.65-1.39 )/839.76912
=-0.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Longboard Pharmaceuticals  (NAS:LBPH) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Longboard Pharmaceuticals Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Executives
Randall Kaye officer: CMO 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller director C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts officer: Chief Financial Officer 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind director, officer: President and CEO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc 10 percent owner 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera officer: Chief Medical Officer C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Headlines